Insider Trading Alert - AMRI, ULTI And MHFI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 13, 2014, 182 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $2,715,292,313,281.00.

Highlighted Stocks Traded by Insiders:

Albany Molecular Research (AMRI) - FREE Research Report

Marth William S, who is President and CEO at Albany Molecular Research, bought 30,000 shares at $15.40 on May 13, 2014. Following this transaction, the President and CEO owned 313,699 shares meaning that the stake was reduced by 10.57% with the 30,000-share transaction.

The shares most recently traded at $15.91, up $0.51, or 3.21% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 8,000

The average volume for Albany Molecular Research has been 682,100 shares per day over the past 30 days. Albany Molecular Research has a market cap of $497.6 million and is part of the health care sector and drugs industry. Shares are up 51.98% year-to-date as of the close of trading on Tuesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 51.3. Currently, there is 1 analyst who rates Albany Molecular Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ultimate Software Group (ULTI) - FREE Research Report

Putten Leroy Vander, who is Director at Ultimate Software Group, sold 2,000 shares at $124.50 on May 13, 2014. Following this transaction, the Director owned 70,667 shares meaning that the stake was reduced by 2.75% with the 2,000-share transaction.

The shares most recently traded at $118.43, down $6.07, or 5.13% since the insider transaction. Historical insider transactions for Ultimate Software Group go as follows:

  • 4-Week # shares sold: 3,412
  • 12-Week # shares sold: 34,412
  • 24-Week # shares sold: 50,412

The average volume for Ultimate Software Group has been 297,600 shares per day over the past 30 days. Ultimate Software Group has a market cap of $3.6 billion and is part of the technology sector and internet industry. Shares are down 22.29% year-to-date as of the close of trading on Tuesday.

The Ultimate Software Group, Inc. provides cloud-based human capital management solutions primarily to enterprise companies. Its UltiPro software solution delivers the functionality businesses to manage the employment life cycle from recruitment to retirement. The company has a P/E ratio of 130.9. Currently, there are 8 analysts who rate Ultimate Software Group a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ULTI - FREE

TheStreet Quant Ratings rates Ultimate Software Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Ultimate Software Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

McGraw Hill Financial (MHFI) - FREE Research Report

Neal Lawrence, who is President, Platts at McGraw Hill Financial, sold 1,000 shares at $79.29 on May 13, 2014. Following this transaction, the President, Platts owned 32,798 shares meaning that the stake was reduced by 2.96% with the 1,000-share transaction.

The shares most recently traded at $78.30, down $0.99, or 1.26% since the insider transaction. Historical insider transactions for McGraw Hill Financial go as follows:

  • 4-Week # shares sold: 10,192
  • 12-Week # shares sold: 14,449
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 17,912

The average volume for McGraw Hill Financial has been 1.7 million shares per day over the past 30 days. McGraw Hill Financial has a market cap of $21.6 billion and is part of the services sector and diversified services industry. Shares are up 1.15% year-to-date as of the close of trading on Tuesday.

McGraw Hill Financial, Inc., a financial intelligence company, provides credit ratings, benchmarks, and analytics to capital and commodity markets worldwide. The stock currently has a dividend yield of 1.51%. The company has a P/E ratio of 24.4. Currently, there are 8 analysts who rate McGraw Hill Financial a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MHFI - FREE

TheStreet Quant Ratings rates McGraw Hill Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full McGraw Hill Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing